Philikos

About Philikos

We develop antibody-based therapies that selectively eliminate overactive immune cells, aiming to restore immune balance without the risks of full immune ablation. Our lead candidate, T-Guard, targets activated T cells and NK cells, which are key drivers in immune-mediated damage. By resetting the immune system, Philikos offers a novel alternative to aggressive treatments like stem cell transplantation.

Philikos: Reset the Immune System, Restore Control.